BCMA News

News

Subgroup of Patients With MM Show Lower T-Cell Count Against COVID-19

12/01/2021

A subgroup of patients with MM who received anti-BCMA or anti-CD38 therapies were found to have lower B and T-cell counts against SARS-CoV-2.

A subgroup of patients with MM...

12/01/2021

Oncology

News

Low Dose GSI, BCMA CAR T-Cell Combo Yields Anti-Tumor Activity in R/R MM

11/10/2021

GSI combined with BCMA CAR T-cell treatment was shown to create deep, tolerable, and durable responses in patients with R/R MM; all data were presented at the 2021 ASH Meeting.

GSI combined with BCMA CAR...

11/10/2021

Oncology

News

Anti-BCMA CAR-T Cell Therapy Found Safe, Effective in Extramedullary MM

10/21/2021

Two phase 1 studies investigate the safety and efficacy of anti-BCMA CAR-T cell therapy for R/R patients with or without extramedullary MM and identify important risk factors.

Two phase 1 studies investigate...

10/21/2021

Oncology

News

Immune Deficiencies Present Following Anti-BCMA CAR-T Cell Therapy in R/R MM

10/04/2021

Researchers investigated recovery durations of patients with R/R multiple myeloma who received BCMA CAR-T cell therapy. Results confirm immune and hematologic deficiencies after treatment.

Researchers investigated...

10/04/2021

Oncology

News

Teclistamab Shows Potential Activity in BCMA-Positive MM

09/30/2020

Data support further examination of teclistamab therapy in the context of patients with MM and BCMA expression.

Data support further examination...

09/30/2020

Oncology

News

Combined Anti-CD19 and Anti-BCMA CAR-T Therapy Feasible for Relapsed/Refractory MM

08/14/2019

The combined use of humanized anti-CD19 and anti-BCMA CAR T-cells is feasible for patients with relapsed or refractory multiple myeloma.

The combined use of humanized...

08/14/2019

Oncology

News

New CAR-T Therapy Less Toxic, More Effective for MM Than Other CAR-Ts

11/29/2018

P-BCMA-101, a novel CAR-T therapy, has demonstrated significant efficacy in patients with relapsed or refractory MM.

P-BCMA-101, a novel CAR-T...

11/29/2018

Oncology

News

Novel CAR-T Drug Promising in Relapsed or Refractory MM

09/11/2018

A new stem cell memory CAR-T therapy has demonstrated exceptional efficacy and safety in patients with relapsed and/or refractory multiple myeloma.

A new stem cell memory CAR-T...

09/11/2018

Oncology

News

CAR T-Cells Targeting BCMA Improve Outcomes in MM

03/27/2018

Multiple studies have demonstrated positive results for CAR T-cells in treating relapsed and refractory MM.

Multiple studies have...

03/27/2018

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology